Scarica l'app Stockscreener
3.21
0.31%
-0.01
Dopo l'orario di chiusura:
3.22
0.01
+0.31%
OncoCyte Corporation Borsa (OCX) Ultime notizie
OncoCyte (NASDAQ:OCX) Now Covered by Lake Street Capital - Armenian Reporter
Lake Street Capital Initiates Coverage on OncoCyte (NASDAQ:OCX) - Defense World
Lake Street starts OncoCyte coverage with Buy, $5 target By Investing.com - Investing.com Canada
OncoCyte’s Strategic Positioning and Growth Potential in Transplant Rejection Testing - TipRanks
OncoCyte initiated with a Buy at Lake Street - TipRanks
Lake Street Initiates Coverage on OncoCyte (OCX) with Buy Rating - GuruFocus.com
OncoCyte a new buy at Lake Street on transplant rejection testing - Seeking Alpha
Lake Street starts OncoCyte coverage with Buy, $5 target - Investing.com India
OncoCyte (NASDAQ:OCX) Given Buy Rating at Needham & Company LLC - Defense World
OncoCyte (NASDAQ:OCX) Receives “Equal Weight” Rating from Stephens - Defense World
OncoCyte Corp’s Positive Earnings Call Highlights Growth - TipRanks
OncoCyte Corp (OCX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Regulatory ... - Yahoo Finance
Earnings call transcript: OncoCyte’s Q4 2024 revenue grows, strategic advances - Investing.com Australia
OncoCyte Corporation (NASDAQ:OCX) Q4 2024 Earnings Call Transcript - Insider Monkey
Needham maintains Buy on OncoCyte, steady $4.25 target By Investing.com - Investing.com South Africa
Needham maintains Buy on OncoCyte, steady $4.25 target - Investing.com
Positive Outlook on OncoCyte’s Stock Due to Strategic Launch and Financial Management - TipRanks
OncoCyte: Q4 Earnings Snapshot - CT Insider
Oncocyte Corp Reports 2024 Success and 2025 Growth Plans - TipRanks
OncoCyte Corp Q4 2024 Earnings: Revenue Surges to $1.5 Million, Beating Estimates; EPS at -0.43 - GuruFocus.com
Oncocyte reports progress in organ transplant diagnostics By Investing.com - Investing.com South Africa
Oncocyte targets $20M in recurring revenue from 20 transplant centers by 2025 - MSN
Earnings call transcript: OncoCyte’s Q4 2024 revenue grows, strategic advances By Investing.com - Investing.com South Africa
OncoCyte Corporation (OCX) Q4 Sales Increase - Nasdaq
Oncocyte reports progress in organ transplant diagnostics - Investing.com India
OncoCyte: Q4 Earnings Snapshot -March 24, 2025 at 04:29 pm EDT - Marketscreener.com
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts - GlobeNewswire
Oncocyte secures $29.1 million to advance FDA assay - MSN
OncoCyte Corp expected to post a loss of 43 cents a shareEarnings Preview - TradingView
Oncocyte corp investor Patrick Smith buys $1,839 in shares - MSN
Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025 - The Manila Times
Oncocyte Sets Key Q4 Earnings Webinar: Live Management Discussion Coming March 24 - StockTitan
OncoCyte Corporation (OCX): Among Top Insider Purchases Last Month - MSN
OncoCyte Announces Executive Promotions and Compensation Changes - TipRanks
OncoCyte Corp. to Host Earnings Call - ACCESS Newswire
OncoCyte stock soars to 52-week high, hits $3.48 By Investing.com - Investing.com Canada
OncoCyte stock soars to 52-week high, hits $3.48 - Investing.com India
OncoCyte Corporation (OCX): Among Penny Stocks with Insider Buying in 2025 - Insider Monkey
Oncocyte Raises $29.1 Million to Develop, Commercialize Transplant Assays - Orange County Business Journal
OncoCyte Corporation (OCX): Among Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
Broadwood Partners acquires OncoCyte shares worth $9.24 million - MSN
OncoCyte stock hits 52-week low at $1.92 amid market challenges - MSN
Oncocyte corp's Patrick Smith acquires shares worth $2.2 million - MSN
Oncocyte corp’s Patrick Smith acquires shares worth $2.2 million By Investing.com - Investing.com South Africa
Oncocyte corp CFO buys $200,000 in stock - MSN
Oncocyte corp CFO buys $200,000 in stock By Investing.com - Investing.com Canada
0.39%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):